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Introduction {#ehf212446-sec-0004}
============

The Impella CP device (Abiomed, Danvers, MA) is indicated for short‐term left ventricular mechanical support (≤4 days) in cardiogenic shock due to acute myocardial infarction (AMI) or planned cardiac surgery.[1](#ehf212446-bib-0001){ref-type="ref"} Current guidelines indicate a class IIb recommendation in patients with therapy refractory cardiogenic shock in ST‐segment elevation myocardial infarction, due to little knowledge on survival benefits.[2](#ehf212446-bib-0002){ref-type="ref"} Even less is known regarding use of the Impella CP in patients with shock due to non‐ischaemic origin. Limited time of operation and missing options for blood oxygenation might favour the use of alternative assist devices such as extracorporeal membrane oxygenation (ECMO) or tandem heart in these indications. However, the minimally invasive nature of Impella therapy and effective ventricular unloading, as compared with increased afterload in ECMO therapy, might in fact favour Impella CP use for bridge‐to‐recovery or destination therapy in such patients. The aim of this study was to investigate the role of Impella CP support in patients with non‐ischaemic cardiogenic shock as compared with shock in AMI.

Methods {#ehf212446-sec-0005}
=======

This single‐centre retrospective case--control study investigated patients who received an Impella CP device due to acute non‐ischaemic cardiogenic shock. Inclusion criteria were therapy refractory haemodynamic instability with severe left ventricular systolic dysfunction and serum lactate \>2.0 mmol/L at implantation, with excluded AMI. Twenty‐five patients were included and compared with 50 patients who received an Impella CP due to AMI with shock during the same period. Outcome measures were haemodialysis, ECMO, or left ventricular assist device implantation, heart transplantation, 30 day survival, and overall in‐hospital mortality. For the univariate analysis, just one variable was fitting at a time in the logistic regression model in order to find which variable is individually predictive. Univariate predictors were analysed in a multivariate analysis. The odds ratio and 95% confidence interval were determined. Statistical analyses were performed using SPSS Statistics 24 (IBM). Continuous variables are expressed as mean ± standard deviation or median (quartiles). Categorical variables are presented as count and per cent.

Results {#ehf212446-sec-0006}
=======

Mean age was 61 ± 13 (range 19--85) years, and 72% were male. Main underlying diseases for cardiogenic shock in the non‐ischaemic group were dilated cardiomyopathy (*n* = 9; 36%), chronic ischaemic cardiomyopathy (*n* = 2; 7.7%), hypertrophic cardiomyopathy (*n* = 2; 7.7%), myocarditis (*n* = 2; 7.7%), catecholamine‐induced cardiomyopathy due to pheochromocytoma (*n* = 1; 3.8%), non‐compaction cardiomyopathy (*n* = 1; 3.8%), takotsubo cardiomyopathy (*n* = 1; 3.8%), and sarcoidosis (*n* = 1; 3.8%).

The need for resuscitation before Impella implantation was frequent in both groups (32 vs. 42%; *P* = 0.402). Patients with non‐ischaemic cardiogenic shock had lower serum levels of lactate dehydrogenase (377 \[279--608\] vs. 616 \[371.3--1109\] U/L; *P* = 0.007) as well as high‐sensitive troponin T (110.65 \[57.87--322.1\] vs. 1610 \[450.8--3861.5\] pg/mL; *P* = 0.001). Glomerular filtration rate (43.5 \[33.2--59.7\] vs. 48 \[35.75--69\] mL/min; *P* = 0.290), C‐reactive protein (5.17 \[3.27--10.26\] vs. 10.97 \[3.23--17.2\] mg/dL; *P* = 0.195), catecholamine index (30.6 \[10.6--116.9\] vs. 47.6 \[11.7--90\] μg/kg/min; *P* = 0.663), and serum lactate (2.6 \[2.2--5.8\] vs. 2.9 \[1.3--6.6\] mmol/L; *P* = 0.424) were comparable. Almost half of the cohort individuals developed sepsis during hospital stay (52.6 vs. 38.5%; *P* = 0.379). Mean ventilation time (3 \[1--12\] vs. 3.5 \[1--13\] days; *P* = 0.738), rates of haemodialysis (52 vs. 47%; *P* = 0.680), and transition to ECMO (13.6 vs. 22.2%; *P* = 0.521) were also comparable, while the non‐ischaemic group showed a trend for longer duration of Impella support (5 \[2--7.5\] vs. 3 \[2--5.25\] days, *P* = 0.211). No significant difference was found regarding in‐hospital mortality (66.7 vs. 74%; *P* = 0.512), although there was a trend for better 30 day survival in the non‐ischaemic group (48 vs. 30%; *P* = 0.126) (*Table* [1](#ehf212446-tbl-0001){ref-type="table"} and *Figure* [*1*](#ehf212446-fig-0001){ref-type="fig"}).

###### 

Clinical characteristics and outcome

  Patient characteristics             Non‐ischaemic shock (n = 25)   Myocardial infarction (n = 50)   P
  ----------------------------------- ------------------------------ -------------------------------- -----------
  Mean age (years)                    59 ± 16                        61.7 ± 11                        0.401
  Mean BMI (kg/m^2^)                  26.5 ± 5.9                     28.3 ± 5                         0.247
  Resuscitation (%)                   8 (32)                         21 (42)                          0.402
  Haemoglobin (g/dL)                  12.2 ± 2.8                     13.3 ± 2.3                       0.100
  Creatinine (mg/dL)                  1.6 (1.24--2.6)                1.33 (1.06--1.96)                0.372
  GFR (mL/min/m^2^)                   43.5 (33.2--59.7)              48 (35.75--69)                   0.290
  CRP (mg/dL)                         5.17 (3.27--10.26)             10.97 (3.23--17.2)               0.195
  LDH (U/L)                           377 (279--608)                 616 (371.3--1109)                **0.007**
  HsTNT (pg/mL)                       110.65 (57.87--322.1)          1610 (450.8--3861.5)             **0.001**
  pH                                  7.33 ± 0.17                    7.29 ± 0.14                      0.293
  Lactate (mmol/L)                    2.6 (2.2--5.8)                 2.9 (1.3--6.6)                   0.424
  Catecholamine index (μg/kg/min)     30.6 (10.6--116.9)             47.6 (11.7--90)                  0.663
  Catecholamine pressure index        0.39 (0.13--1.4)               0.6 (0.18--1.1)                  0.592
  Catecholamine index after implant   30.66 (20.65--78.57)           33.34 (19.9--69.8)               0.981
  Mean duration of Impella (days)     5 (2--7.5)                     3 (2--5.25)                      0.211
  Mean ventilation time (days)        3 (1--12)                      3.5 (1--13)                      0.738
  Intermittent haemodialysis (%)      13 (52)                        23 (47)                          0.680
  Systolic pressure explant (mmHg)    85.1 ± 20.5                    92 ± 24.7                        0.328
  MAP explant (mmHg)                  63.5 ± 20.5                    68.9 ± 14.1                      0.243
  ECMO (%)                            3 (13.6)                       10 (22.2)                        0.521
  LVAD (%)                            1 (4.0)                        3 (6.0)                          1
  Heart transplantation (%)           4 (16)                         0 (0)                            **0.010**
  30 day survival (%)                 12 (48)                        15 (30)                          0.126
  Overall in‐hospital mortality (%)   16 (66.7)                      37 (74)                          0.512

BMI, body mass index; CRP, C‐reactive protein; ECMO, extracorporeal membrane oxygenation; GFR, glomerular filtration rate; HsTNT, high‐sensitive troponin T; LDH, lactate dehydrogenase; LVAD, left ventricular assist device; MAP, mean arterial pressure.

![Thirty day survival in ischaemic vs. non‐ischaemic shock](EHF2-6-863-g001){#ehf212446-fig-0001}

Several predictors for mortality were identified including serum lactate, ventilation time, haemoglobin, pH, SaO~2~, base excess, glucose, bleeding anaemia, resuscitation, sepsis, and Impella time (*Table* [2](#ehf212446-tbl-0002){ref-type="table"}). From the patients with non‐ischaemic cardiogenic shock and without mechanical device support (ECMO and left ventricular assist device) or transplantation, only 24% (six from 25) survived. In the resuscitation group, only 21% (six from 29) survived, compared with 36% in the total cohort (27 from 75).

###### 

Predictors of mortality

  Predictor                         Coefficient   SE coefficient   Z        P           Odds ratio   95% CI   
  --------------------------------- ------------- ---------------- -------- ----------- ------------ -------- --------
  Acute myocardial infarction                                                                                 
  Lactate (mmol/L)                  0.100         0.040            6.270    **0.012**   1.106        1.022    1.196
  Ventilation (days)                0.054         0.023            5.369    **0.020**   0.947        0.905    0.992
  Haemoglobin (g/dL)                0.356         0.098            0.854    **0.001**   1.427        1.178    1.728
  pH                                4.469         1.468            9.265    **0.002**   0.011        0.001    0.204
  SaO2 (%)                          0.066         0.029            5.178    **0.023**   0.936        0.885    0.991
  BE (mmol/L)                       0.066         0.039            2.838    0.092       0.937        0.868    1.011
  Glucose (mg/dL)                   0.001         0.001            2.360    0.124       1.001        1.000    1.003
  Bleeding anaemia                  1.048         0.455            5.307    **0.021**   0.351        0.144    0.855
  Resuscitation                     0.939         0.363            6.674    **0.010**   2.557        1.254    5.212
  Sepsis                            0.386         0.533            0.524    0.469       1.471        0.517    4.183
  Impella time (days)               0.308         0.110            7.903    **0.005**   0.735        0.592    0.911
  MAP                               0.058         0.016            13.152   **0.001**   0.944        0.915    0.974
  Non‐ischaemic cardiogenic shock                                                                             
  Lactate (mmol/L)                  0.114         0.088            1.692    0.193       1.121        0.944    1.332
  Ventilation (days)                0.152         0.075            4.119    **0.042**   0.859        0.742    0.995
  Haemoglobin (g/dL)                0.278         0.232            1.438    0.231       1.321        0.838    2.081
  pH                                1.940         1.899            1.044    0.307       0.144        0.003    5.936
  SaO2 (%)                          0.057         0.042            1.888    0.169       0.944        0.870    1.025
  BE (mmol/L)                       0.049         0.042            1.330    0.249       0.952        0.876    1.035
  Glucose (mg/dL)                   0.006         0.003            3.324    0.068       1.006        1.000    1.013
  Bleeding anaemia                  12.059        8.838            0.001    0.975       0.320        0.123    0.715
  Resuscitation                     0.365         0.579            0.399    0.528       1.441        0.464    4.480
  Sepsis                            1.090         0.734            2.205    0.138       2.975        0.705    12.545
  Impella time (days)               0.962         0.333            8.357    **0.004**   0.382        0.199    0.734
  MAP                               0.040         0.019            4.575    **0.032**   0.961        0.926    0.997
  Total group                                                                                                 
  Lactate (mmol/L)                  0.118         0.038            9.924    **0.002**   1.125        1.046    1.211
  Ventilation (days)                0.057         0.022            6.951    **0.008**   0.944        0.905    0.985
  Haemoglobin (g/dL)                0.131         0.067            0.854    **0.050**   1.140        1.000    1.299
  pH                                3.634         1.134            10.276   **0.001**   0.026        0.003    0.244
  SaO2 (%)                          0.063         0.0237           0.586    **0.006**   0.939        0.898    0.982
  BE (mmol/L)                       0.063         0.0285           0.233    **0.022**   0.939        0.889    0.991
  Glucose (mg/dL)                   0.002         0.001            5.136    **0.023**   1.002        1.000    1.003
  Bleeding anaemia                  1.078         0.445            5.860    **0.015**   0.340        0.142    0.815
  Resuscitation                     0.807         0.2967           0.447    **0.006**   2.241        1.255    4.002
  Sepsis                            0.847         0.421            4.047    **0.044**   2.334        1.022    5.329
  Impella time (days)               0.431         0.099            18.905   **0.000**   0.650        0.535    0.789
  MAP                               0.120         0.069            6.665    **0.002**   0.941        0.916    0.987

BE, base excess; CI, confidence interval; MAP, mean arterial pressure.

Conclusions {#ehf212446-sec-0007}
===========

Thirty day mortality in our study generally was high, mainly driven by post‐resuscitation mortality. However, overall survival rates were similar to those found in recent large shock trials.[3](#ehf212446-bib-0003){ref-type="ref"}, [4](#ehf212446-bib-0004){ref-type="ref"}, [5](#ehf212446-bib-0005){ref-type="ref"} Our current data suggest that benefit of Impella CP therapy might be similar in non‐ischaemic compared with ischaemic shock. Moreover, a substantial percentage of patients without acute ischaemia recovered without further need for intensified haemodynamic mechanical support. Of note, a relatively large proportion of patients in the non‐ischaemic cohort initially suffered from chronic cardiomyopathies. Here, several alternatives for bridge‐to‐recovery or destination therapy are available. Just recently, feasibility of the larger Impella 5.0 in bridge‐to‐heart transplantation was demonstrated.[6](#ehf212446-bib-0006){ref-type="ref"} The current results position short‐time use of the Impella CP as an alternative in the treatment of patients with cardiogenic shock due to underlying non‐ischaemic cardiomyopathy and/or complicating additional factors. However, additional studies are needed to test whether these findings can be confirmed in larger patient populations and which subgroups might benefit most from Impella therapy.
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